NASDAQ Composite opens in less than five hours and Novavax‘s pre-market value is already 5.72% up.
The last session, NASDAQ Composite finished with Novavax sliding 7.41% to $180.67. NASDAQ Composite slid 1.88% to $13,633.50, after three consecutive sessions in a row of losses, on what was an all-around negative trend exchanging session.
Novavax’s last close was $195.12, 83.58% under its 52-week high of $331.68.
Year-on-year quarterly revenue growth grew by 3072.2%, now sitting on 475.6M for the twelve trailing months.
Novavax’s last day, last week, and last month’s current volatility was 21.43%, 9.27%, and 5.28%, respectively.
Novavax’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 26.21% (day), 13.79% (last week), and 9.14% (last month), respectively.
Previous days news about Novavax
Novavax begins testing its Covid-19 vaccine candidate in teens. According to MarketWatch on Monday, 3 May, "Shares of Novavax Inc. gained 0.6% in trading on Monday after the biotechnology firm said it has expanded its Phase 3 clinical trial for its COVID-19 vaccine candidate to include 12 to 17 year olds in the U.S. Novavax’s experimental vaccine is currently being tested in a late-stage trial that began in December in the U.S. and Mexico. "
More news about Novavax.